Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-01

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study duration for individual patients will be up to 55 weeks for the 4-weekly and 3- weekly schedule of the treatment which includes 3 weeks for screening, 48 weeks for Study Medication administration and 4 weeks for follow-up assessments

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

NCT00751621

Primary Immunodeficiency (PID)

COMPLETED PHASE3

Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection

NCT01659684

Cytomegalovirus Congenital Infection

UNKNOWN NA

Minipooled-IVIG in Primary Immunodeficiency Disease

NCT03896932

Primary Immunodeficiency

COMPLETED NA

Identification of New Inborn Errors of Immunity

NCT03414528

Primary Immune Deficiency Disorder

UNKNOWN

Systematic Screening for Primary Immunodeficiencies in Patients Admitted for Severe Infection in Pediatric Intensive Care Unit

NCT04990908

Severe Infection Severe Immune Deficiency

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible subjects will receive either test or reference as per the randomization in 1:1 ratio.

Test group: V-Immune will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose.

Reference group: Immuglo will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Immunodeficiency Diseases (PID)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Treatment - Randomized - parallel group study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Open label

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Arm

200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose.

Group Type EXPERIMENTAL

IVIG-VImmune

Intervention Type DRUG

V-Immune will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose

Reference

Immuglo will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose

Group Type ACTIVE_COMPARATOR

IVIG-Immuglo

Intervention Type DRUG

Immuglo will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IVIG-VImmune

V-Immune will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose

Intervention Type DRUG

IVIG-Immuglo

Immuglo will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female, aged 2 to 65 years.
2. Patients with confirmed diagnosis of primary immunodeficiency, predominantly antibody deficient, or common variable immunodeficiency (CVID) with a history of hypogammaglobulinemia (i.e., IgG\<500 mg/dl) or X-linked agammaglobulinemia (XLA).
3. Treatment naive patients eligible to receive intravenous immunoglobulin or, patients already on intravenous immunoglobulin infusions every 3 or every 4 weeks for ≥6 months at a dose aimed to be between 200 and 800 mg/kg with at least two documented IgG trough levels in the previous two infusions before enrolment in the study.
4. The screening laboratory tests must meet the following criteria:

1. WBC ≥3.5 x 109/L
2. Neutrophils ≥1.5 x 109/L
3. Platelets ≥100 x 109/L
4. Serum transaminase ≤2 times the upper limit of normal
5. Alkaline phosphatase levels ≤2 times the upper limit of normal
6. Serum creatinine ≤150 µmol/L (≤1.7mg/dl)
5. Patients must be able to adhere to the study visit schedule and other protocol requirements.
6. If subject is a female and is

a. -of child bearing potential, she should be practicing an acceptable method of birth control for the duration of tl1e study as suggested by the investigator, such as a combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier method), intrauterine device (IUD), or abstinence OR surgically sterile, bilateral tubal ligation done at least 6 months before the study should be documented
7. Patients/LAR must be capable of giving informed consent, and written consent must have been obtained prior to any study procedures.

Exclusion Criteria

1. Pregnant women, nursing mothers or a planned pregnancy within 18 months of participation.
2. Patients requires any blood transfusion during the study.
3. Patients with T-cell related Severe combined immunodeficiency.
4. Patients with secondary immunodeficiency diseases
5. History or presence of any form of cancer prior to enrollment.
6. History of any autoimmune disease
7. Positive at screening for any markers of infectious blood borne viruses
8. History of adverse or allergic reactions to other IgG or blood products
9. Patients with selective IgA deficiency or antibodies IgA
10. History of acute renal failure or severe renal impairment, or deep venous thrombosis which in the opinion of the Investigator, may place the patient at unacceptable risk for study participation and may prevent the patient from completing the study.
11. History of congestive heart failure \[New York Heart Association class III/IV\] or unstable angina
12. Recent history of migraine, hyperprolinemia, and lymphoid malignancy.
13. Requirement for use of glucocorticosteroids above 0.15 mg of prednisone equivalent/kg/day and other immunosupressive drugs as concomitant medication.
14. History or presence of any medical or psychiatric condition or disease, or laboratory abnormality that, in the opinion of the Investigator, may place the patient at unacceptable risk for study participation and may prevent the patient from completing the study.
15. Participation in any clinical study within the previous 3 months
16. Patient, who in the opinion of the Investigator, is not suitable for participation in the clinical study

Minimum Eligible Age

2 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No